Please assess the completion status of the following clinical trial:

Trial Title: Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy White, male volunteers between 18 and 55 years of age (inclusive).~* BMI between 19 and 28 kg/m² (inclusive).~Exclusion Criteria:~* Previous participation in a clinical study with rotigotine~* History or current condition of epilepsy and/or seizures.~* Known clinically relevant allergy or known/suspected clinically relevant drug hypersensitivity.~* History of significant skin hypersensitivity to adhesives or other transdermal products or recently unresolved contact dermatitis.~* History or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease.~* Clinically relevant abnormality in physical examination, ECG, vital signs or safety laboratory examinations.~* Positive HIV, hepatitis B or C test or positive alcohol or drug test.~* Relevant hepatic or renal dysfunction~* Intake of medication that might interfere with the test drug within 2 weeks prior to dosing.~* Thickly hair-covered abdomen resulting in difficulties in finding appropriate patch application sites

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Sequence A-B (Test: PR2.1.1 - Reference: PR1.0) (Type: EXPERIMENTAL): Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days
- Sequence B-A (Reference: PR1.0 - Test: PR2.1.1) (Type: EXPERIMENTAL): Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).